139 related articles for article (PubMed ID: 38495452)
1. Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.
Seung SJ; Saherawala H; Zagorski B; Tong C; Lim H; Kim P; Marquez V; Gill S; Liu D; Davies JM
Hepat Oncol; 2023 Dec; 10(4):HEP50. PubMed ID: 38495452
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada.
Seung SJ; Saherawala H; Kim Y; Tieu J; Wang S; Shephard C; Bossé D
Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927937
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea.
Novick D; Cho JM; Colman S; Szende A
Drugs Real World Outcomes; 2022 Jun; 9(2):263-274. PubMed ID: 34905182
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
6. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
[TBL] [Abstract][Full Text] [Related]
8. Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.
Yi TW; Atiquzzaman M; Zheng Y; Smyth B; Jardine M; Levin A
Can J Kidney Health Dis; 2022; 9():20543581221145068. PubMed ID: 36578697
[TBL] [Abstract][Full Text] [Related]
9. The Return on Investment of a Province-Wide Quality Improvement Initiative for Reducing In-Hospital Sepsis Rates and Mortality in British Columbia, Canada.
Khowaja AR; Willms AJ; Krause C; Carriere S; Ridout B; Kennedy C; Young E; Mitton C; Kissoon N; Sweet DD
Crit Care Med; 2022 Apr; 50(4):e340-e350. PubMed ID: 34593705
[TBL] [Abstract][Full Text] [Related]
10. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era.
Shah C; Mramba LK; Bishnoi R; Bejjanki H; Chhatrala HS; Chandana SR
J Gastrointest Oncol; 2017 Oct; 8(5):789-798. PubMed ID: 29184682
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.
O'Sullivan DE; Boyne DJ; Syed IA; Shephard C; Clouthier DL; Yoshida EM; Spratlin JL; Batra A; Rigo R; Hannouf M; Yang Hu X; N Jarada T; Brenner DR; Cheung WY
Can Liver J; 2022 Nov; 5(4):476-492. PubMed ID: 38144405
[No Abstract] [Full Text] [Related]
12. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan.
Nguang SH; Wu CK; Liang CM; Tai WC; Yang SC; Ku MK; Yuan LT; Wang JW; Tseng KL; Hung TH; Hsu PI; Wu DC; Chuah SK; Hsu CN
Int J Environ Res Public Health; 2018 Nov; 15(12):. PubMed ID: 30486324
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics, Treatment Patterns, and Healthcare Costs and Utilization for Hepatocellular Carcinoma (HCC) Patients Treated at a Large Referral Center in Washington State 2007-2018.
Shankaran V; Chennupati S; Sanchez H; Sun Q; Li L; Fedorenko C; Aly A; Healey M; Seal B
J Hepatocell Carcinoma; 2021; 8():1597-1606. PubMed ID: 34938673
[TBL] [Abstract][Full Text] [Related]
14. Health care costs associated with hepatocellular carcinoma: a population-based study.
Thein HH; Isaranuwatchai W; Campitelli MA; Feld JJ; Yoshida E; Sherman M; Hoch JS; Peacock S; Krahn MD; Earle CC
Hepatology; 2013 Oct; 58(4):1375-84. PubMed ID: 23300063
[TBL] [Abstract][Full Text] [Related]
15. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
17. Developing an efficient scheduling template of a chemotherapy treatment unit: A case study.
Ahmed Z; Elmekkawy T; Bates S
Australas Med J; 2011; 4(10):575-88. PubMed ID: 23386870
[TBL] [Abstract][Full Text] [Related]
18. Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma: A Population-based Study.
Tsang ES; Davies JM; Loree JM; Lim HJ; Renouf DJ; Gill S
Am J Clin Oncol; 2020 Nov; 43(11):788-791. PubMed ID: 32868523
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
20. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
